Skip to Content

Posts tagged with "Drug Industry History"

  • Drug Assays

    A Quick Survey of the Landscape

    I think, at this point in the history of medicinal chemistry, that we’re now trying to define just what the limits of med-chem might be. By that, I mean small molecules, as opposed to biologics. The early days of the field were naturally a lot more wide open, since there were so many targets that… Read More
  • Drug Industry History

    Company Time For Your Own Ideas, Or Not?

    Over the years, at many R&D-driven companies, there have been official/unofficial policies that researchers could spend some percent of their time pursuing their own ideas, versus their official projects and goals. You hear different figures, especially when it comes to past glories, but there are definitely companies that have made this a stat… Read More
  • Business and Markets

    Infinity’s Research, From Someone Who Was There

      Here’s a look from the inside at Infinity Pharmaceuticals, whose R&D operations hit the wall just recently. Keith Robison knows the company and its targets well, having worked there until about five years ago, and he provides a perspective that some others in the readership will have experienced as well: So it was a… Read More
  • Business and Markets

    Infinity’s Difficult History

    Infinity Pharmaceuticals today announced that it’s shutting down R&D operations. This comes after disappointing clinical results for a PI3K inhibitor it’s been developing (duvelisib), news which has sent the company’s stock down (at this moment) nearly 70%. And that comes after the 2012 failure of another clinical candidate, s… Read More
  • Clinical Trials

    Are Things Getting Any Better in the Clinic?

    Here’s an updated look at clinical success rates in the biotech industry, from the BIO industry organization. They’re looking at only company-sponsored programs aimed at FDA registration, nothing investigator-sponsored, and it’s a big data set: This is the largest study of clinical drug development success rates to date. Over the… Read More
  • Business and Markets

    The Baseless Fabric of This Vision

    Not everyone is going to sit still and listen to someone from GlaxoSmithKline talk about how to most effectively deploy chemists (and wonder where more of them might be coming from). If you’re up for it, here’s the article at Drug Discovery Today. It’s not trying to hide the situation, though (links added for the original… Read More
  • Cardiovascular Disease

    CETP Finally Heads to the Trash Heap?

    The tale of CETP (cholesteryl ester transfer protein) as a drug target has been long, and convoluted, and expensive, and horrendously disappointing. Pfizer failed, Roche failed, several other companies like BMS who didn’t even get that far failed, and last fall Lilly’s entry failed, too (that link has links to several past blog posts he… Read More
  • Drug Development

    The Puritan Impulse

    Here’s a good blog post with a lot of food for thought, and here’s the follow-up. I missed these back when they came out last year, but the issues they raise are (for better or worse) evergreen. The author’s framing a debate about medicinal chemistry as Cavaliers-versus-Roundheads, which is a classification that’s useful en… Read More
  • Animal Testing

    A Terrific Paper on the Problems in Drug Discovery

    Here’s a really interesting paper from consultants Jack Scannell and Jim Bosley in PLoS ONE, on the productivity crisis in drug discovery. Several things distinguish it: for one, it’s not just another “whither the drug industry” think piece, of which we have plenty already. This one get quantitative, attempting to figure out… Read More
  • Academia (vs. Industry)

    Drugs Purely From Academia

    I see that there’s an investment fund in Europe saying that “Every year, around 30 to 40 percent of the drugs approved by the FDA (U.S. Food and Drug Administration) were actually discovered in European academic labs“. Meanwhile the European Medicines Agency says that “Academia and other public-private partnerships helped to… Read More